Pill Identifier App

Six Abstracts Featuring Exelixis Compounds Accepted At ASCO Conference

- Phase I data from XL880, Phase II data from XL999 studies scheduled for presentation during oral, poster sessions -

SOUTH SAN FRANCISCO, May 30, 2007 /PRNewswire-FirstCall/ -- Exelixis, Inc. announced today that data from clinical trials of the company's investigational compounds XL880 and XL999 will be presented at the 2007 American Society of Clinical Oncology Annual Meeting (ASCO), which is being held June 1 to 5 in Chicago, Illinois.

    -- Data from the Phase I trials of XL880 will be presented and discussed

       during the Developmental Therapeutics: Molecular Therapeutics oral

       abstract presentation session at 9:00 a.m. CT on Saturday, June 2, in

       room E354b. (Abstract #3526)


    -- Data from the Phase II trials of XL999 will be presented and discussed

       during the Developmental Therapeutics: Molecular Therapeutics poster

       session at 8:00 a.m. on Sunday, June 3, in S Hall A2. (Abstract #3591)


Additionally, four abstracts from Phase I studies of XL184 (Abstract #14031), XL647 (Abstract #14044) and Phase II studies of XL880 (Abstract #15601) and XL999 (Abstract #18112) will be published in abstract form but will not be presented at the meeting.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in Phase II and Phase I clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.

CONTACT: investors, Charles Butler, Director, Corporate Communications,+1-650-837-7277, , or media, Soleil Maxwell Harrison,Senior Manager, Corporate Communications, +1-650-837-7012, both of Exelixis, Inc. cbutler@exelixis.com sharrison@exelixis.com

Web site: http://www.exelixis.com/

Ticker Symbol: (NASDAQ-NMS:EXEL)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: May 2007

View comments

Hide
(web3)